Advertisement

Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention

  • Lan Shen
  • Chiara MelloniEmail author
Women + Heart Disease (J Robinson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Women and Heart Disease

Abstract

Cardiovascular disease (CVD) is the leading cause of mortality in women. Differences in pathophysiology, diagnosis, and treatment of women with cardiovascular disease compared with men have become a major focus during the past decades. Guideline of CVD prevention in women drew heavily on the results of randomized clinical trials (RCT). However, data from RCT in women was limited, leading to concerns of women been underrepresented in clinical trials from which guidelines were generated. During the past several years, researchers, physicians, and regulators have made substantial efforts to improve understanding of the sex difference in CVD and to recognize the importance of heart disease in women. The purpose of this review is to evaluate contemporary sex differences in CVD disease management, current representation of women in RCT, and examine factors that may improve women’s representation and quality of care in CVD prevention in women.

Keywords

Cardiovascular disease Women Randomized clinical trial 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Chiara Melloni declares no conflicts of interest. Lan Shen declares no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: A report from the american heart association. Circulation. 2013;127:e6–245.PubMedCrossRefGoogle Scholar
  2. 2.
    Elixhauser A JH. Hospitalizations for women with circulatory disease, 2003.Hcup statistical brief no .5 .Rockville, md: Agency for healthcare research and quality; 2006. 2006;2014Google Scholar
  3. 3.
    Us department of health and human services, administration on aging. A profile of older americans: 2011. 2011;2014.Google Scholar
  4. 4.•
    Lam CS, Little WC. Sex and cardiovascular risk: Are women advantaged or men disadvantaged? Circulation. 2012;126(8):913–5. doi: 10.1161/CIRCULATIONAHA.112.121582. This study showed sex difference in cardiology study.PubMedCrossRefGoogle Scholar
  5. 5.
    Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. J Fam Pract. 2000;49:147–52.PubMedGoogle Scholar
  6. 6.
    Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. Gender disparities in the diagnosis and treatment of non-st-segment elevation acute coronary syndromes: Large-scale observations from the crusade (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the american college of cardiology/american heart association guidelines) national quality improvement initiative. J Am Coll Cardiol. 2005;45:832–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Vaccarino V, Rathore SS, Wenger NK, Frederick PD, Abramson JL, Barron HV, et al. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med. 2005;353:671–82.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, et al. Sex differences in medical care and early death after acute myocardial infarction. Circulation. 2008;118:2803–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Health TSfWsHRUSFaDAOoWs. Dialogues on diversifying clinical trials: Successful strategies for engaging women and minorities in clinical trials. 2011.Google Scholar
  10. 10.
    Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res. 2002;53:550–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010;3:135–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708–13.PubMedCrossRefGoogle Scholar
  13. 13.
    Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the national heart, lung, and blood institute. N Engl J Med. 2000;343:475–80.PubMedCrossRefGoogle Scholar
  14. 14.•
    Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: Have we made progress? J Womens Health. 2011;20:315–20. This study showed women's underrepresentation in clinical trials.CrossRefGoogle Scholar
  15. 15.
    Fernandez-Saez J, Ruiz-Cantero MT, Guijarro-Garvi M, Carrasco-Portino M, Roca-Perez V, Chilet-Rosell E, et al. Looking twice at the gender equity index for public health impact. BMC Public Health. 2013;13:1471–2458.CrossRefGoogle Scholar
  16. 16.
    Phillips SP. Including gender in public health research. Public Health Rep. 2011;3:16–21.Google Scholar
  17. 17.
    Office USGA. Women's health: Fda needs to ensure more study of gender differences in prescription drug testing. (gao/ hrd-93-17). 1992.Google Scholar
  18. 18.
    Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol. 2007;49:1230–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Dhruva SS, Redberg RF. Evaluating sex differences in medical device clinical trials: Time for action. JAMA. 2012;307:1145–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Warner Jr JG, Brubaker PH, Zhu Y, Morgan TM, Ribisl PM, Miller HS, et al. Long-term (5-year) changes in hdl cholesterol in cardiac rehabilitation patients. Do sex differences exist? Circulation. 1995;92:773–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Wizemann TM, Pardue M. Exploring the biological contributions to human health: Does sex matter? Washington, D.C.: National Academy Press; 2001.Google Scholar
  22. 22.
    Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2001;2:349–51.PubMedCrossRefGoogle Scholar
  23. 23.
    Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: Evolving knowledge. J Am Coll Cardiol. 2009;54:1561–75.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Dhruva SS, Bero LA, Redberg RF. Gender bias in studies for food and drug administration premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011;4:165–71.PubMedCrossRefGoogle Scholar
  25. 25.
    National insitutes of health revitalization act of 1993. Pub. L. No.103-43, 107 stat 122. 1993Google Scholar
  26. 26.
    Administration USFaD. Guidance for industry: Collecti of race and ethnicity data in clinical trials. 2005;2014.Google Scholar
  27. 27.
    Berger JS, Bairey-Merz CN, Redberg RF, Douglas PS. Improving the quality of care for women with cardiovascular disease: Report of a dcri think tank, march 8 to 9, 2007. Am Heart J. 2008;156:816–25.PubMedCrossRefGoogle Scholar
  28. 28.
    Kanarek NF, Tsai HL, Metzger-Gaud S, Damron D, Guseynova A, Klamerus JF, et al. Geographic proximity and racial disparities in cancer clinical trial participation. J Natl Compr Canc Netw. 2010;8:1343–51.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Biswas MS, Calhoun PS, Bosworth HB, Bastian LA. Are women worrying about heart disease? Womens Health Issues. 2002;12:204–11.PubMedCrossRefGoogle Scholar
  30. 30.
    Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of american women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes. 2010;3:120–7.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499–510.PubMedCrossRefGoogle Scholar
  32. 32.
    Powell JH, Fleming Y, Walker-McGill CL, Lenoir M. The project impact experience to date: Increasing minority participation and awareness of clinical trials. J Natl Med Assoc. 2008;100:178–87.PubMedGoogle Scholar
  33. 33.
    Feinberg J, Saag M, Squires K, Currier J, Ryan R, Coate B, et al. Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat. 2011;349165:28.Google Scholar
  34. 34.•
    Falcon R, Bridge DA, Currier J, Squires K, Hagins D, Schaible D, et al. Recruitment and retention of diverse populations in antiretroviral clinical trials: Practical applications from the gender, race and clinical experience study. J Womens Health. 2011;20:1043–50. This study showed the an example of community driven approach of clinical trial.CrossRefGoogle Scholar
  35. 35.
    Mosca L, Barrett-Connor E, Kass Wenger N. Sex/gender differences in cardiovascular disease prevention: What a difference a decade makes. Circulation. 2011;124:2145–54.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1481–501.PubMedCrossRefGoogle Scholar
  37. 37.
    Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. American heart association scientific statement. Arterioscler Thromb Vasc Biol. 2004;24:e29–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, et al. Guidelines for the prevention of stroke in women: A statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2014;6:6.Google Scholar
  39. 39.
    Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: A guideline from the american heart association. Circulation. 2011;123:1243–62.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    van der Weijden T, Grol R. Preventing recurrent coronary heart disease. We need to attend more to implementing evidence based practice. BMJ. 1998;316(7142):1400–1.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Leape LL, Weissman JS, Schneider EC, Piana RN, Gatsonis C, Epstein AM. Adherence to practice guidelines: The role of specialty society guidelines. Am Heart J. 2003;145:19–26.PubMedCrossRefGoogle Scholar
  42. 42.
    Cook D, Giacomini M. The trials and tribulations of clinical practice guidelines. JAMA. 1999;281(20):1950–1.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of CardiologyShanghai Renji HospitalShanghaiChina
  2. 2.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA

Personalised recommendations